Eosinophilic Asthma clinical trials

Explore recruiting eosinophilic asthma clinical trials.

Recruiting eosinophilic asthma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Eosinophilic Asthma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2b, Randomized, Double blind, Placebo controlled, Parallel group, Multicenter, Dose ranging Study Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Adult Participants with Uncontrolled Moderate to Severe Eosinophilic Asthma

Spain, Romania, Slovakia, Poland, Germany, Italy +2 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 24 weeks in participants with eosinophilic asthma (EXHALE-4)

Romania, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

BRISOTE: A Multicentre, Randomised, Double-blind, Parallel Group, Active-Controlled, Phase 3b Study to Evaluate the Efficacy and Safety of Benralizumab 30 mg SC in Eosinophilic Asthma Patients Uncontrolled on Medium-Dose Inhaled Corticosteroid Plus Long-acting β2 Agonist

Italy, France, Ireland, Spain, Norway, Germany +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

The IMAGINE study: A phase 3b open label, single arm study to assess the effect of depemokimab on airway structure and function in asthma with Type 2 inflammation characterized by an eosinophilic phenotype utilizing quantitative high-resolution CT and bronchoscopic airway sampling in a sub study

Belgium, Spain, Italy, Greece, France, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A prospective, real-world, interventional study to evaluate the effect of mepolizumab on achieving clinical remission in participants with severe asthma.

Italy, Belgium, France, Spain, Germany, Poland

Therapeutic use (Phase IV) EU CTIS Study details

An Open-Label Long-Term Phase III Extension Study to Assess the Long-Term Safety and Tolerability of Dexpramipexole in Participants with Severe Eosinophilic Asthma (EXHALE-5)

Poland, Romania, Bulgaria, Czechia, Germany, Italy +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Eosinophilic Asthma trials by city

Eosinophilic Asthma in Toronto Eosinophilic Asthma in Vancouver Eosinophilic Asthma in Montreal Eosinophilic Asthma in Calgary Eosinophilic Asthma in Edmonton Eosinophilic Asthma in Ottawa Eosinophilic Asthma in Winnipeg Eosinophilic Asthma in Quebec City Eosinophilic Asthma in Hamilton Eosinophilic Asthma in Kitchener Eosinophilic Asthma in London Eosinophilic Asthma in Halifax Eosinophilic Asthma in New York Eosinophilic Asthma in Los Angeles Eosinophilic Asthma in Chicago Eosinophilic Asthma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease